Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  C. Deswarte,et al.  Clonal haematopoiesis is increased in early onset in systemic sclerosis. , 2020, Rheumatology.

[3]  Javier Martín,et al.  Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome , 2019, The Korean journal of internal medicine.

[4]  A. List,et al.  The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. , 2019, Blood.

[5]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[6]  O. Decaux,et al.  Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .

[7]  S. Inoue,et al.  Roles of IDH1/2 and TET2 mutations in myeloid disorders , 2016, International Journal of Hematology.

[8]  Harri Lähdesmäki,et al.  Control of Foxp3 stability through modulation of TET activity , 2016, The Journal of experimental medicine.

[9]  J. Piette,et al.  Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.

[10]  P. Fenaux,et al.  Myelodysplastic syndromes , 2014, The Lancet.

[11]  R. Tibshirani,et al.  Automated identification of stratifying signatures in cellular subpopulations , 2014, Proceedings of the National Academy of Sciences.

[12]  P. Fenaux,et al.  Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? , 2013, Best practice & research. Clinical haematology.

[13]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[14]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[15]  G. Mufti,et al.  IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome , 2009, British journal of haematology.

[16]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.